| 10.01.2024 08:25 | GSK | GSK says Nucala gets green light in China for asthma treatment | Alliance |
| 10.01.2024 07:00 | GSK | Nucala approved in China for use in severe asthma | RNS |
| 09.01.2024 08:03 | GSK | TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion | Alliance |
| 09.01.2024 07:00 | GSK | GSK enters agreement to acquire Aiolos Bio | RNS |
| 04.01.2024 14:01 | XPS, WWH, SMWH | UK dividends calendar - next 7 days | Alliance |
| 03.01.2024 09:23 | GNC, ROO, CWK | LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold' | Alliance |
| 02.01.2024 15:00 | GSK | Total Voting Rights | RNS |
| 21.12.2023 15:30 | GSK | Director/PDMR Shareholding | RNS |
| 20.12.2023 16:44 | GSK | Publication of EMTN Suppl.Prospcts | RNS |
| 18.12.2023 10:07 | GSK | GSK's dostarlimab trial in endometrial cancer meets primary endpoint | Alliance |
| 18.12.2023 07:00 | GSK | Jemperli plus Zejula Trial Meets Endpoint | RNS |
| 15.12.2023 16:29 | GSK, AZN | PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg | Alliance |
| 13.12.2023 15:30 | GSK | Director/PDMR Shareholding | RNS |
| 12.12.2023 08:22 | GSK | TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine | Alliance |
| 12.12.2023 07:00 | GSK | Japan accepts Arexvy filing for at risk adults | RNS |
| 11.12.2023 08:28 | GSK | GSK drug gets EU marketing backing for form of endometrial cancer | Alliance |
| 11.12.2023 07:00 | GSK | Jemperli plus chemotherapy EU authorisation | RNS |
| 07.12.2023 12:54 | HLN, GSK, WTB | THG backer Kelso pushes for demerger to trim "inherent" valuation gap | Alliance |
| 05.12.2023 10:02 | ENT, CPG, AZN | LONDON BROKER RATINGS: Goldman lifts Landsec and British Land | Alliance |
| 04.12.2023 15:02 | GSK | GSK publishes provisional 2024 dividend dates | RNS |
| 01.12.2023 15:00 | GSK | Total Voting Rights | RNS |
| 30.11.2023 09:00 | GSK | Block Listing Application | RNS |
| 29.11.2023 15:23 | GSK | Holding(s) in Company | RNS |
| 27.11.2023 09:00 | GSK | GSK announces positive results from Blenrep phase 3 blood cancer trial | Alliance |
| 27.11.2023 07:00 | GSK | GSK announces positive DREAMM-7 headline results | RNS |
| 22.11.2023 09:48 | DEVO, FDEV, KWS | LONDON BROKER RATINGS: RBC cuts HSBC; Liberum cuts Glencore | Alliance |
| 21.11.2023 15:30 | GSK | Director/PDMR Shareholding | RNS |
| 21.11.2023 11:52 | GSK | GSK to begin phase 3 trials of low-carbon Ventolin inhaler in 2024 | Alliance |
| 15.11.2023 15:00 | GSK | Block listing Interim Review | RNS |
| 13.11.2023 15:30 | GSK | Director/PDMR Shareholding | RNS |
| 13.11.2023 09:47 | GSK | GSK hails momelotinib opinion from European Medicines Agency committee | Alliance |
| 13.11.2023 07:00 | GSK | GSK receives positive CHMP opinion for momelotinib | RNS |
| 09.11.2023 15:50 | WIN, ULVR, UKCM | UK dividends calendar - next 7 days | Alliance |
| 08.11.2023 09:30 | ITM, CRE, WOSG | LONDON BROKER RATINGS: UBS downbeat on AJ Bell and Hargreaves Lansdown | Alliance |
| 02.11.2023 10:14 | ASC, GLB, DSCV | LONDON BROKER RATINGS: Bank of America starts Unite Group with 'buy' | Alliance |
| 01.11.2023 15:00 | GSK | Total Voting Rights | RNS |
| 01.11.2023 08:51 | GSK | TOP NEWS: GSK ups guidance as boosted by Shingrix and Arexvy | Alliance |
| 01.11.2023 07:00 | GSK | 3rd Quarter Results | RNS |
| 30.10.2023 09:01 | GSK | IN BRIEF: GSK says Jemperli meets endpoint in endometrial cancer trial | Alliance |
| 30.10.2023 07:00 | GSK | Jemperli trial meets overall survival endpoint | RNS |
| 26.10.2023 09:19 | GSK | TOP NEWS: GSK subsidiary ViiV receives HIV drug approval in China | Alliance |
| 26.10.2023 07:00 | GSK | NMPA approves Vocabria+Rekambys in China | RNS |
| 25.10.2023 16:01 | WEIR, SKG, NXT | UK earnings, trading statements calendar - next 7 days | Alliance |
| 25.10.2023 15:30 | GSK | Director/PDMR Shareholding | RNS |
| 25.10.2023 09:35 | GSK | GSK says RSV jab shows promising response in adults aged 50 to 59 | Alliance |
| 25.10.2023 07:00 | GSK | New data for Arexvy, GSK’s RSV vaccine | RNS |
| 20.10.2023 15:30 | GSK | Director/PDMR Shareholding | RNS |
| 18.10.2023 15:30 | GSK | Director/PDMR Shareholding | RNS |
| 17.10.2023 15:30 | GSK | Director/PDMR Shareholding | RNS |
| 16.10.2023 08:09 | GSK | TOP NEWS: GSK receives positive EU opinion on Jemperli for cancer | Alliance |
| 16.10.2023 07:00 | GSK | Jemperli plus chemotherapy positive CHMP opinion | RNS |
| 13.10.2023 15:30 | GSK | Director/PDMR Shareholding | RNS |
| 12.10.2023 15:30 | GSK | Director/PDMR Shareholding | RNS |
| 11.10.2023 09:17 | AFM, AIBG, BIRG | LONDON BROKER RATINGS: JPMorgan raises Croda; Berenberg cuts Atalaya | Alliance |
| 11.10.2023 08:36 | GSK | TOP NEWS: GSK reaches settlement for Zantac litigation in California | Alliance |
| 11.10.2023 07:00 | GSK | Zantac (ranitidine) litigation | RNS |
| 10.10.2023 11:00 | GSK, HLN | Holding(s) in Company | RNS |
| 09.10.2023 08:16 | GSK | TOP NEWS: GSK inks agreement with Zhifei to promote shingles vaccine | Alliance |
| 09.10.2023 07:00 | GSK | GSK and Zhifei announce vaccine partnership | RNS |
| 06.10.2023 07:57 | HLN, GSK | UPDATE: GSK banks GBP886 million from Haleon share sale | Alliance |
| 06.10.2023 07:00 | GSK | GSK completes sale of shares in Haleon plc | RNS |
| 05.10.2023 16:46 | GSK | GSK announces intention to sell shares in Haleon | RNS |
| 05.10.2023 15:47 | XPP, WPP, TTG | UK dividends calendar - next 7 days | Alliance |
| 03.10.2023 18:19 | GSK | IN BRIEF: GSK's Jemperli approved in UK for endometrial cancer | Alliance |
| 02.10.2023 15:00 | GSK | Total Voting Rights | RNS |
| 27.09.2023 15:00 | GSK | Directorate Change | RNS |
| 25.09.2023 09:13 | ASLI, IHR, WHR | LONDON BROKER RATINGS: Jefferies raises AstraZeneca to 'buy' | Alliance |
| 25.09.2023 08:37 | GSK | TOP NEWS: GSK's Arexvy vaccine approved for adults over 60 in Japan | Alliance |
| 25.09.2023 07:00 | GSK | GSK RSV vaccine for older adults approved in Japan | RNS |
| 21.09.2023 15:30 | GSK | Director/PDMR Shareholding | RNS |
| 19.09.2023 09:30 | GSK | GSK says new HIV PrEP medication authorised by European Commission | Alliance |
| 19.09.2023 07:00 | GSK | Apretude for PrEP receives EMA approval | RNS |
| 18.09.2023 09:40 | BPCR, FEVR, SFOR | LONDON BROKER RATINGS: Jefferies likes Energean; JPMorgan raises IDS | Alliance |
| 18.09.2023 07:00 | GSK | FDA approves Ojjaara (momelotinib) | RNS |
| 15.09.2023 21:52 | GSK | GSK's Ojjaara approved in US for myelofibrosis patients with anaemia | Alliance |
